Nikolaus R McFarland
Affiliation: Massachusetts General Hospital
- Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal systemNikolaus R McFarland
MassGeneral Institute for Neurodegenerative Disease MIND, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129 4404, USA
J Neurochem 109:838-45. 2009..New rAAV serotypes thus promise improved gene delivery to nigrostriatal system with the potential for better models and therapeutics for Parkinson disease and other neurodegenerative disorders...
- Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson diseaseNikolaus R McFarland
MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129 4404, USA
J Neuropathol Exp Neurol 68:515-24. 2009..Further study is needed to clarify the effects of these S129 mutants and alpha-synuclein phosphorylation in mammalian systems...
- Postmortem brain levels of urate and precursors in Parkinson's disease and related disordersNikolaus R McFarland
Center for Translational Research in Neurodegenerative Disease, Department of Neurology, University of Florida College of Medicine, Gainesville, Fla, USA
Neurodegener Dis 12:189-98. 2013..In Parkinson's disease (PD) higher, but still normal, levels of blood and cerebrospinal fluid urate have been associated with a lower rate of disease progression...